From the TRINN Archives
by Rafel Solamis
TRI-HQ (TRI-FP) – In what appears to be an attempt to recoup losses after a the recent tit for tat corporate squabbles, Tens & Piney, Cromforge Enterprises, and Octave Propulsion Labs have all offered up similar investment opportunities as part of their bids to win the exclusive manufacturing rights for the Letifer virus cure from Samsun Universal.
“Tens & Piney is pleased to offer the chance at a good investment opportunity for enterprising pilots,” stated Vivian Duvazaco. “When T&P wins the cure bid, those pilots who invested will be richly rewarded for their foresight and financial savvy as their initial investment gets doubled. In addition, T&P commits to ensuring the cure is made available as fast as possible to any government who has citizens suffering from this terrible disease.”
“Cromforge is committed to bringing this cure to the people of Perasca,” remarked Cila Rotup’uh. “It is our intention to offer this cure to the Fa’hil Memta at cost price. Cromforge is not out to make a profit, nor reverse engineer the cure into a new virus, but simply to help those who are suffering.”
“Only Octave Propulsion has the vision for this project,” commented Zru Tudezaw. “Anyone with an ounce of common sense will see that investing in the OPL bid offers an almost guaranteed chance to double their money in a very short period of time. We have a proven track record of taking the initiative, and thinking out of the box to bring products to market faster than our competitors.”
All three investments close at 23:59 ET on 105.03.17 and any pilot wishing to partake should contact the corporations directly.